Today the FDA published a notice in the Federal Register regarding a public hearing to be held May 31 in Silver Spring Maryland. Requests to present in person are due by May 10 and the deadline for written comments is July 2nd. Details on how to submit comments are included in the notice.
Date: May 31, 2019
Time: 8:00 a.m. – 6:00 p.m.
Location: FDA’s White Oak Campus
Building 31, Room 1503 – Great Room
10903 New Hampshire Avenue
Silver Spring, Maryland 20993
Statement From FDA Commissioner
Commissioner Scott Gottlieb also issued a statement in which he outlined steps that FDA plans to take to advance their consideration of a framework for the lawful marketing of appropriate cannabis and cannabis-derived products under our existing authorities. These new steps include:
Commissioner Scott Gottlieb also issued a statement in which he outlined steps that FDA plans to take to advance their consideration of a framework for the lawful marketing of appropriate cannabis and cannabis-derived products under our existing authorities. These new steps include:
- A public hearing on May 31, as well as a broader opportunity for written public comment, for stakeholders to share their experiences and challenges with these products, including information and views related to product safety.
- The formation of a high-level internal agency working group to explore potential pathways for dietary supplements and/or conventional foods containing CBD to be lawfully marketed; including a consideration of what statutory or regulatory changes might be needed and what the impact of such marketing would be on the public health.
- Updates to FDA’s webpage with answers to frequently asked questions on this topic to help members of the public understand how the FDA’s requirements apply to these products.
- The issuance of multiple warning letters to companies marketing CBD products with egregious and unfounded claims that are aimed at vulnerable populations.
Vote Hemp intends to submit comments to FDA and share those with you. We urge you to consider submitting comments to FDA telling them about your experiences with hemp extracts and hemp derived CBD products. We also ask you to urge FDA to keep a path open for hemp derived foods and dietary supplements that contain CBD and other useful phytocompounds.